Short Wave Why Aduhelm, a new Alzheimer's treatment, isn't reaching many patients
Nov 5, 2021
Jon Hamilton, NPR science correspondent, dives into Aduhelm, the first Alzheimer's drug targeting the disease's underlying process. He highlights its limited patient reach due to high costs and controversy over its effectiveness. Despite initial excitement, both doctors and patients exhibit skepticism about its efficacy and risks. Hamilton also discusses barriers like complex administration and eligibility challenges, leaving many wondering about the future of Alzheimer's treatment in light of these significant obstacles.
AI Snips
Chapters
Transcript
Episode notes
Aduhelm's Slow Uptake
- Aduhelm, a new Alzheimer's drug, has underwhelming sales.
- Very few patients use it despite its potential to impact the disease.
Aduhelm's Image Problem
- Aduhelm faces an image problem due to high cost, risks, and uncertain benefits.
- Doctors are divided on its value, impacting patient adoption.
Aduhelm's Drawbacks
- Aduhelm is expensive, only for early-stage patients, has side effects, and lacks strong efficacy evidence.
- Despite limited alternatives, its drawbacks hinder widespread adoption.